PATIENT ALERT: Information regarding COVID-19. 

Clinical Research & Trials

USO 20164

A Phase II, Multicenter, Open Label Study Of Bintrafusp Alfa (M7824) Monotherapy In Participants With HMGA2-Expressing Triple Negative Breast Cancer (MS200647_0020)

 

Disease Types: Breast Cancer Research

Eligibility Requirements:

-Must have measurable disease that has progressed on most recent line of therapy with at least one line of systemic therapy for metastatic disease
-No active CNS disease that requires therapeutic intervention
-No prior treatment with immunotherapy or checkpoint inhibitors
-No history of organ or stem cell transplant, clinically significant cardio/cerebral vascular disease – stroke, myocardial infarction, unstable angina, congestive 
heart failure, serious cardiac arrythmia, interstitial lung disease, or pnuemonitis

Available at: